L3VLUP
ProSign in

IQV · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IQVLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IQV
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterIQVLLY
Q3 202021 holders, $4.8bn33 holders, $14.1bn
Q4 202022 holders, $5.2bn29 holders, $17.3bn
Q1 202118 holders, $5.4bn24 holders, $23.0bn
Q2 202126 holders, $6.1bn24 holders, $27.8bn
Q3 202124 holders, $5.9bn31 holders, $29.9bn
Q4 202124 holders, $6.9bn31 holders, $34.7bn
Q1 202221 holders, $5.2bn24 holders, $35.3bn
Q2 202215 holders, $3.9bn33 holders, $42.7bn
Q3 202221 holders, $3.1bn31 holders, $43.4bn
Q4 202219 holders, $3.9bn31 holders, $46.6bn
Q1 202324 holders, $4.4bn33 holders, $44.3bn
Q2 202323 holders, $5.5bn37 holders, $59.6bn
Q3 202322 holders, $5.4bn44 holders, $67.6bn
Q4 202314 holders, $6.2bn45 holders, $73.6bn
Q1 202415 holders, $6.9bn41 holders, $95.3bn
Q2 202420 holders, $5.8bn43 holders, $110bn
Q3 202423 holders, $6.3bn45 holders, $107bn
Q4 202422 holders, $5.7bn46 holders, $93.9bn
Q1 202522 holders, $5.1bn42 holders, $98.4bn
Q2 202521 holders, $5.4bn43 holders, $93.2bn
Q3 202517 holders, $5.9bn39 holders, $86.7bn
Q4 202518 holders, $7.0bn41 holders, $123bn
Q1 202611 holders, $4.7bn39 holders, $106bn
Q2 202619 holders, $5.3bn44 holders, $132bn
IQV

Iqvia HLDGS Inc

Holders
23
Reported value
$6.3bn
Buyers
15
Sellers
7

Breadth +8 among 94 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 50 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IQV (5)

Farallon Capital Management LLC, Harris Associates LP, Markel Group Inc, PDT Partners LLC, Tybourne Capital Management HK Ltd

Only LLY (27)

Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Jane Street Group LLC, MFS Investment Management, Millennium Management LLC, Polen Capital Management LLC, Renaissance Technologies LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, Susquehanna International Group LLP, T. Rowe Price Associates Inc, Tiger Global Management LLC, Verition Fund Management LLC, Viking Global Investors LP, Voloridge Investment Management LLC, Walleye Capital LLC, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →